Group 1 - The Fourth Global Digital Trade Expo opened in Hangzhou, where Dean Diagnostics signed a strategic cooperation agreement with Hangzhou Data Group to co-build a trusted data space for the city [1] - The collaboration aims to create advanced and secure infrastructure for the trusted data space, explore market-oriented data allocation mechanisms, and promote efficient data circulation to enhance the regional digital economy [1][2] - Dean Diagnostics will leverage its high-quality data resources in the medical diagnostics field to establish a trusted data sub-space for the industry, facilitating compliant data circulation and commercial applications [1][2] Group 2 - Dean Diagnostics has developed high-quality data sets across various fields, including oncology, infections, chronic diseases, and maternal and child health, based on over 20 years of service to more than 22,000 medical institutions [2] - The company plans to transition from a data provider to a data operator and value co-creator, establishing a closed-loop ecosystem of "data-service-application" [2] - The launch of the "Smart Inspection Link - Integrated Management Platform for Regional Testing/Pathology" aims to address challenges in regional healthcare, enhancing digital capabilities in grassroots medical services [3]

Core Viewpoint - Health 160 (02656.HK) successfully listed on the Hong Kong Stock Exchange, with a significant opening increase of 150.96%, reflecting strong investor interest and a market capitalization exceeding HKD 10 billion [2][4] Company Overview - Health 160 is a leading digital healthcare service provider in China, focusing on a dual business model of "pharmaceutical health product sales" and "digital healthcare solutions" [4][5] - The company has established a vast network connecting over 44,600 healthcare institutions and 902,300 healthcare professionals, serving more than 55.2 million registered users across over 260 cities [6] Financial Performance - The company has shown steady revenue growth over the past three years, with revenues of RMB 525.6 million, RMB 628.6 million, and RMB 620.7 million for 2022, 2023, and 2024 respectively [6] - The adjusted net loss has significantly narrowed from RMB 81.95 million in 2022 to RMB 35.69 million in 2023, and further to RMB 31.47 million in 2024 [6] Market Position and Growth Potential - Health 160 is recognized as the largest digital healthcare service platform in China, with a projected market size of RMB 740.1 billion by 2030, growing at a compound annual growth rate of 22.4% from 2024 to 2030 [7] - The successful listing is expected to enhance the company's market position and accelerate the comprehensive layout of its digital health service ecosystem [7]

Core Viewpoint - Health 160 International Limited is preparing for an IPO on the Hong Kong Stock Exchange, having submitted its prospectus after hearing, with plans to issue up to 61.45 million shares [1][2]. Company Overview - Health 160 is a leading Chinese pharmaceutical and health products wholesaler and a digital healthcare service provider, offering a wide range of health products and comprehensive digital healthcare solutions [3]. - The company operates the largest digital healthcare service platform in China, based on the number of registered users and partnered hospitals by the end of 2024 [3]. Business Model - Health 160 provides health products through a wholesale model to corporate clients and a retail model to individual users [3]. - The digital healthcare solutions are delivered via the Health 160 platform, connecting various stakeholders in the healthcare industry, including enterprises, healthcare institutions, healthcare professionals, and individual users [3]. Market Reach - As of March 31, 2025, Health 160 has expanded its services to over 260 cities in China and established 11 regional operation centers in key areas such as Shenzhen, Beijing, Shanghai, and Guangzhou [4]. - The platform connects over 44,600 healthcare institutions, including more than 14,400 hospitals and 30,200 grassroots healthcare institutions [4]. Partnerships and User Base - The company collaborates with over 6800 private healthcare institutions primarily providing consumer medical services [5]. - Health 160 has established partnerships with over 902,300 healthcare professionals and has a registered user base of 55.2 million, with an average of 3.3 million monthly active users in 2024 [6]. Shareholder Structure - The major shareholder, Mr. Luo Ningzheng, holds 33.99% of the shares through Luo Holdings Limited, with additional voting rights from Ming Holdings Limited [7][8]. Financial Performance - Health 160's revenue for the years 2022, 2023, 2024, and the first three months of 2025 were RMB 526 million, RMB 629 million, RMB 621 million, and RMB 100 million, respectively, with corresponding net losses of RMB 120 million, RMB 106 million, RMB 108 million, and RMB 17 million [11][12].

Core Viewpoint - Health 160 International Limited is preparing for its listing on the Hong Kong Stock Exchange, with Shenwan Hongyuan Hong Kong and Qianhai Capital acting as joint sponsors [1]. Company Overview - Health 160 is an experienced wholesale distributor of pharmaceutical health products and a leading provider of integrated digital healthcare services in China. The company offers a variety of pharmaceutical health products and comprehensive digital healthcare solutions [4]. - The company operates a digital healthcare service platform, Health 160, which connects healthcare institutions, healthcare professionals, and individual users, facilitating the digital transformation of the healthcare industry in China [5]. Digital Healthcare Solutions - The Health 160 platform integrates online and offline healthcare services, providing a diverse range of medical services, including serious and consumer healthcare services. The platform employs effective monetization strategies to generate revenue from various participants [5]. - As of March 31, 2025, the platform has connected over 44,600 healthcare institutions, including more than 14,400 hospitals (3,430 of which are tertiary hospitals) and over 30,200 grassroots healthcare institutions [5]. Partnerships and User Base - The company has established partnerships with over 902,300 healthcare professionals, including approximately 46,200 registered doctors. The platform has a substantial user base, with 55.2 million registered individual users and an average of 3.3 million monthly active users as of March 31, 2025 [6]. Financial Performance - The company's revenue for the years ending December 31 for 2022, 2023, and 2024, and for the three months ending March 31, 2025, was approximately RMB 526 million, RMB 629 million, RMB 621 million, and RMB 100 million, respectively. The company reported losses of approximately RMB 120 million, RMB 106 million, RMB 108 million, and RMB 17 million for the same periods [6][7].

Core Viewpoint - Health 160 International Limited is seeking to list on the Hong Kong Stock Exchange after a previous application lapsed, aiming to issue up to 61.45 million shares [3]. Company Overview - Established in 2005, Health 160 provides a range of pharmaceutical health products and comprehensive digital healthcare solutions, facilitating the digital transformation of the healthcare industry in China [5][9]. - The company has built a digital healthcare service platform that offers reliable online health services, breaking the limitations of traditional offline healthcare services [5]. Market Position - According to a Frost & Sullivan report, Health 160 ranks first among major industry players in terms of the number of registrations through its platform as of 2023, and third in revenue generated from digital healthcare solutions [5]. Service Network - As of June 30, 2024, Health 160's platform connects over 33,700 healthcare institutions, including more than 14,200 hospitals and over 19,400 grassroots healthcare institutions [6]. - The company collaborates with over 740,000 healthcare professionals and has registered 48.9 million individual users, with an average of 3 million monthly active users in the first half of 2024 [6]. Revenue Sources - Health 160's revenue comes from the sale of pharmaceutical health products and the provision of digital healthcare solutions [7]. Financial Performance - The company's revenue for the years 2021, 2022, 2023, and the first half of 2024 was RMB 422.83 million, RMB 525.65 million, RMB 628.61 million, and RMB 273.82 million respectively [14]. - The net losses for the same periods were RMB 152.41 million, RMB 120.07 million, RMB 106.20 million, and RMB 83.26 million [14]. Shareholder Structure - The pre-IPO shareholder structure includes Luo Ningzheng holding 33.99% through Luo Holdings Limited, and several entities controlled by Fu Zhekuan holding various percentages [8]. Management Team - The board of directors consists of 9 members, including the CEO Luo Ningzheng and several vice presidents [13][15].